Clinical Trial Update: Myfortic vs. Cellcept in Kidney Transplant Recipients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial comparing mycophenolate mofetil formulations (Myfortic vs. Cellcept) in kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• MYFORTIC (MYCOPHENOLIC ACID)

Snippet

Sponsor: University of Miami | Conditions: End Stage Renal Disease | Phase 2, Phase 3 | Status: COMPLETED